Marc Peeters, MD, PhD, department of oncology, Antwerp University Hospital, Antwerpen, Belgium, discusses the importance of properly managing the toxicities associated with aflibercept when treating patients with metastatic colorectal cancer.
There is an impression that treatment with aflibercept is associated with more toxicity than bevacizumab, based on findings from the VELOUR trial. However, Peeters believes, when examining findings from clinical practice and cohort studies it seems clear that aflibercept-related side effects can be managed without altering dose intensity or schedule. As a result, familiarity with managing drug-related toxicity is important, to optimize treatment.
<<< View more from the World GI Congress